Litigation settlement gain (loss)
Year-over-year, this metric grew by 100.9%, from -$110.00M to $1.00M. Over 4 years (FY 2022 to FY 2026), Litigation settlement gain (loss) shows an upward trend with a -71.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
A gain improves net income temporarily, while a loss indicates a negative legal outcome or settlement payment.
Detailed definition
The net financial impact resulting from the resolution of legal proceedings, including settlements, judgments, or insura...
Peer comparison
Common in large-cap companies; investors look for these as non-recurring items to adjust earnings.
pfe_litigation_settlement_gain_lossHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$74.00M | -$112.00M | -$7.00M | -$279.00M | -$5.00M | $9.00M | $1.00M | $6.00M | $0.00 | $2.00M | $0.00 | -$39.00M | -$112.00M | $4.00M | $0.00 | -$110.00M | $0.00 | $2.00M | $0.00 | $1.00M |
| QoQ Change | — | -51.4% | +93.8% | <-999% | +98.2% | +280.0% | -88.9% | +500.0% | -100.0% | — | -100.0% | — | -187.2% | +103.6% | -100.0% | — | +100.0% | — | -100.0% | — |
| YoY Change | — | — | — | — | +93.2% | +108.0% | +114.3% | +102.2% | +100.0% | -77.8% | -100.0% | -750.0% | — | +100.0% | — | -182.1% | +100.0% | -50.0% | — | +100.9% |
Business Segments — U.S. Pharmaceutical
| Segment | Q4 '24 | Q1 '25 |
|---|---|---|
| U.S. Pharmaceutical | -$18.50M | -$57.00M |
| Corporate | -$18.75M | — |
| Total | -$39.00M | -$112.00M |
Corporate, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments — North American Pharmaceutical Segment and Corporate Expenses
| Segment | FY'25 |
|---|---|
| North American Pharmaceutical Segment and Corporate Expenses | $57.00M |
| Total | -$218.00M |
All segment values are derived from annual filings.
Litigation settlement gain (loss) at Other Companies
Frequently Asked Questions
- What is McKesson's litigation settlement gain (loss)?
- McKesson (MCK) reported litigation settlement gain (loss) of $1.00M in Q1 2026.
- How has McKesson's litigation settlement gain (loss) changed year-over-year?
- McKesson's litigation settlement gain (loss) increased by 100.9% year-over-year, from -$110.00M to $1.00M.
- What is the long-term trend for McKesson's litigation settlement gain (loss)?
- Over 4 years (2022 to 2026), McKesson's litigation settlement gain (loss) has grown at a -71.8% compound annual growth rate (CAGR), from -$472.00M to $3.00M.
- What does litigation settlement gain (loss) mean?
- Net financial gains or losses from legal settlements.